When should hydrochlorothiazide (HCTZ) be used in hypertension versus indapamide?

When to Use Indapamide Over HCTZ in Hypertension

Indapamide should be preferentially used over hydrochlorothiazide (HCTZ) for hypertension treatment in most clinical scenarios. Both major international guidelines now group these as "thiazide-type diuretics" but acknowledge important differences in potency and half-life, particularly relevant for resistant hypertension 1, 2.

Why Indapamide is Superior

Blood Pressure Reduction

Indapamide demonstrates significantly greater antihypertensive efficacy than HCTZ:

• Systolic BP reduction: 5.1 mmHg greater than HCTZ (95% CI: -8.7 to -1.6 mmHg; P=0.004) 3
• Diastolic BP reduction: 1.98 mmHg greater than HCTZ (95% CI: -3.29 to -0.66 mmHg; P=0.003) 4
• This superiority persists even when HCTZ is used at higher dose levels 3

Metabolic Safety Profile

Critically, indapamide achieves superior BP control without increased metabolic adverse effects:

• No difference in hypokalemia incidence compared to HCTZ 3, 4
• No difference in hyponatremia risk 4
• No difference in effects on blood glucose or total cholesterol 4

Clinical Outcomes Evidence

HCTZ lacks mortality and cardiovascular event reduction data when used as monotherapy 5, 6. In contrast:

• Indapamide has demonstrated cardiovascular event reduction in clinical trials 7
• HCTZ actually increased cardiovascular death and coronary artery disease compared to placebo in 2 randomized trials 5

Guideline-Based Recommendations

The 2024 ESC Guidelines recommend thiazides/thiazide-like drugs (chlorthalidone and indapamide) as Class I, Level A first-line treatments 2. The 2025 AHA/ACC Guidelines acknowledge these agents collectively but note that "differences in potency and half-life between these agents may be relevant in some situations, particularly in the management of resistant hypertension" 1.

Practical Dosing Algorithm

For Initial Hypertension Treatment:

• Start indapamide 1.25 mg once daily (taken in morning) 8
• If inadequate response after 4 weeks → increase to 2.5 mg daily 8
• If still inadequate after 4 weeks → increase to 5 mg daily OR add another antihypertensive 8

For HCTZ (if indapamide unavailable):

• Requires 25 mg twice daily or 50 mg daily for equivalent stone prevention 7
• For hypertension: 12.5-25 mg daily 9

When HCTZ Might Be Acceptable

HCTZ may be considered only in these limited scenarios:

• As add-on therapy to other drug classes where it has demonstrated safety (12.5-25 mg daily) 7
• Cost or availability constraints make indapamide inaccessible
• Patient already well-controlled on HCTZ without adverse effects (though switching to indapamide would likely provide better control)

Critical Caveats

Resistant Hypertension

For three-drug combinations not achieving target BP, the guideline-recommended sequence is 2:

1. RAS blocker + CCB + thiazide/thiazide-like diuretic
2. Add spironolactone (Class IIa recommendation)
3. Consider eplerenone, beta-blocker, or centrally-acting agent

In resistant hypertension specifically, indapamide's greater potency and longer half-life make it clearly preferable to HCTZ 1.

Safety Concerns

• Skin cancer risk: Health Canada issued a 2019 warning about HCTZ's association with increased skin cancer risk, though this had only transient impact on prescribing patterns 10
• Hyponatremia correction: Chlorthalidone shows slower correction rates at 96 hours; indapamide and HCTZ are comparable 11

Adherence Considerations

Thiazides as a class have poorer adherence rates than other antihypertensive classes 6. Single-pill combinations are strongly recommended (Class I, Level B) to improve adherence 2.

Bottom Line Algorithm

1. First-line diuretic choice: Indapamide 1.25-2.5 mg daily
2. Combination therapy: Indapamide + ACE inhibitor or ARB (preferably as single-pill combination)
3. Resistant hypertension: Indapamide is mandatory over HCTZ due to potency differences
4. HCTZ use: Reserve only for add-on therapy when indapamide unavailable or in stable patients already tolerating it

The evidence overwhelmingly favors indapamide over HCTZ for superior blood pressure reduction, equivalent metabolic safety, and actual cardiovascular outcome data 3, 4, 7, 5, 6.